ALX Oncology Holdings Inc. (ALXO) Fair Value 2026

ALXO · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.2 /10

32 fundamental signals · 1 models active

Value Trap Risk

LOW (34/100)

Quick Summary — As of 2026-08-28, ALX Oncology Holdings Inc. (ALXO) trades at $2.00. QOC: 5.2/10. Value Trap Risk: 34/100 (LOW). 1/13 models active.

Key Facts

Ticker
ALXO
Price
$2.00
Quality Score
5.2/10
Value Trap Risk
34/100
Models Active
1/13
Last Updated
Strength: 1 independent models provide multi-angle coverage
Risk: Majority of models suggest overvaluation

What Fair Value Does Each Model Give ALXO?

1 Intrinsic Value Models vs. Current Price ($2.00)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $0.26 -87.0%

All Models Active

All 1 models are displayed above.

What Is ALX Oncology Holdings Inc. (ALXO) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, ALX Oncology Holdings Inc.'s intrinsic value is estimated at $0.26. Trading at its current price of $2.00, the valuation engine raises significant caution: 1 of 1 models flag downside risk, projecting a median implied return of -87.0%.

What Do the Models Say About ALXO?

1 of 13 models are currently active for ALXO. All 1 active models suggest the stock trades above fair value. See which stocks rank higher →

How Does ALXO Rank in Biotechnology?

Among 625 Biotechnology stocks, ALXO ranks #268 by Quality of Company score. CirclFi's QOC score of 5.2/10 evaluates 32 fundamental signals. A score of 5.2 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

The Biotechnology sector introduces analytical considerations specific to biotechnology enterprise businesses. For ALX Oncology Holdings Inc., metrics like R&D burn rate provide important context that general-purpose valuation models may underweight.

Is ALXO a Value Trap?

CirclFi's Value Trap algorithm assigns ALXO a score of 34/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for ALX Oncology Holdings Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, ALX Oncology Holdings Inc. scores 5.2 out of 10 on our 32-signal quality assessment, a moderate rating that shows mixed signals across our quality framework with notable weaknesses. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every ALXO valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across ALXO's 1 active models, average confidence is 57%. Moderate confidence indicates reasonable fit.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy ALX Oncology Holdings Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

NKTXNkarta, Inc.QOC 5.2SABSSAB Biotherapeutics, Inc.QOC 5.2MLECMoolec Science SAQOC 5.2IMTXImmatics N.V.QOC 5.2DAREDaré Bioscience, Inc.QOC 5.2ALMSAlumis Inc.QOC 5.2CDIOCardio Diagnostics Holdings, Inc.QOC 4.6ADTXAditxt, Inc.QOC 3.4QUREuniQure N.V.QOC 6.3EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: NKTX · SABS · MLEC · IMTX · DARE · ALMS · CDIO · ADTX · QURE · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to ALXO?

5 companies across all industries closest to ALXO’s Quality of Company score of 5.2/10.

FLNTFluent, Inc.QOC 5.2GLUThe Gabelli Global Utility & Income TrustQOC 5.2DAICCID HoldCo, Inc.QOC 5.2CNETZW Data Action Technologies Inc.QOC 5.2NVDANVIDIA CorporationQOC 10.0

Read investment analysis: FLNT · GLU · DAIC · CNET · NVDA

Where Does ALXO Sit in CirclFi's Biotechnology Rankings?

ALXO is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About ALX Oncology Holdings Inc.’s Valuation?

What is ALX Oncology Holdings Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for ALX Oncology Holdings Inc. (ALXO). The Quality of Company score is 5.2/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is ALXO overvalued or undervalued right now?

At $2.00, 0 of 1 active models suggest ALXO may be undervalued, while 1 indicate potential overvaluation. The assessment depends on which methodology best fits ALX Oncology Holdings Inc.'s business model in Biotechnology.

What does a Quality of Company score of 5.2 mean for ALXO?

ALX Oncology Holdings Inc.'s QOC of 5.2/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on ALXO?

CirclFi analyzes ALXO with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is ALXO a value trap in 2026?

ALX Oncology Holdings Inc.'s Value Trap score is 34/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns ALX Oncology Holdings Inc. (ALXO) a Quality of Company score of 5.2/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/ALXO/ · Methodology
Primary sources for this ALXO valuation
  • Financial statements: ALX Oncology Holdings Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001810182) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for ALXO as of ; valuations recomputed .